Bruker Corporation (NASDAQ:BRKR) Receives $50.38 Average PT from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have earned a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $50.3846.

BRKR has been the topic of several recent research reports. The Goldman Sachs Group lowered their price target on shares of Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research note on Friday, February 13th. Barclays reduced their price objective on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Monday, December 29th. Jefferies Financial Group set a $50.00 target price on Bruker in a research report on Thursday, February 12th. Finally, Wolfe Research upgraded Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a report on Wednesday, December 10th.

Bruker Trading Down 0.0%

NASDAQ BRKR opened at $35.80 on Monday. The stock has a market capitalization of $5.45 billion, a price-to-earnings ratio of -238.67, a PEG ratio of 2.14 and a beta of 1.19. The stock’s 50 day moving average price is $40.63 and its two-hundred day moving average price is $41.17. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). The business had revenue of $977.20 million for the quarter, compared to the consensus estimate of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker’s revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts anticipate that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be paid a dividend of $0.05 per share. The ex-dividend date is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s dividend payout ratio is currently -133.33%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $35.44, for a total value of $70,880.00. Following the completion of the sale, the vice president owned 128,443 shares of the company’s stock, valued at approximately $4,552,019.92. This represents a 1.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 11,000 shares of company stock valued at $554,280. Corporate insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of institutional investors have recently added to or reduced their stakes in the company. Sector Gamma AS increased its stake in shares of Bruker by 28.0% during the 3rd quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock worth $8,152,000 after purchasing an additional 54,939 shares during the last quarter. Becker Capital Management Inc. lifted its stake in Bruker by 606.8% in the 3rd quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock valued at $9,800,000 after purchasing an additional 258,545 shares during the last quarter. DNB Asset Management AS lifted its stake in Bruker by 40.5% in the 3rd quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock valued at $4,654,000 after purchasing an additional 41,289 shares during the last quarter. Aquatic Capital Management LLC grew its holdings in Bruker by 120.3% during the third quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock worth $11,358,000 after purchasing an additional 190,883 shares during the period. Finally, M&G PLC grew its holdings in Bruker by 233.0% during the third quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock worth $35,079,000 after purchasing an additional 766,992 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.